10-Q: Aligos Therapeutics Reports Q3 2024 Financial Results and Provides Business Update

Aligos Therapeutics, a clinical-stage biopharmaceutical company, released its third quarter 2024 financial results, highlighting progress in its clinical programs and financial position.

Summary

• Aligos Therapeutics reported a net loss of $19.3 million for the three months ended September 30, 2024, and a net loss of $49.1 million for the nine months ended September 30, 2024.
• The company's cash, cash equivalents, and investments totaled $74.9 million as of September 30, 2024.
• Revenue from collaborations decreased to $19 thousand for the three months ended September 30, 2024, and $311 thousand for the nine months ended September 30, 2024, primarily due to the completion of the Amended Agreement with Merck.
• Revenue from customers increased to $1.3 million for the three months ended September 30, 2024, and decreased to $3.0 million for the nine months ended September 30, 2024, due to the near completion of the original agreement with Amoytop and the start of the extension agreement.
• Research and development expenses increased to $16.8 million for the three months ended September 30, 2024, and $54.2 million for the nine months ended September 30, 2024, primarily due to increased clinical study costs.
• General and administrative expenses decreased to $4.6 million for the three months ended September 30, 2024, and $17.7 million for the nine months ended September 30, 2024, primarily due to reduced legal and IP spend and decreased employee-related costs.
• The company expects its existing cash, cash equivalents and investments will enable it to fund its operations for at least 12 months following the date the condensed consolidated financial statements are issued.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive clinical data and a strong cash position, the company is still incurring significant losses and faces substantial risks. The decrease in collaboration revenue is a concern.

Positives

• ALG-055009 demonstrated a favorable tolerability profile with no evidence of clinical hyper/hypothyroidism.
• ALG-000184 continued to be well tolerated with no viral breakthrough.
• ALG-097558 has been shown to be at least 6-fold more potent than nirmatrelvir and other PIs in clinical development against a panel of SARS-CoV-2 variants.
• The company has a strong cash position to fund operations for at least 12 months.

Negatives

• The company has incurred net losses in each year since its formation.
• Revenue from collaborations decreased significantly due to the completion of the Amended Agreement with Merck.
• The company is dependent on third parties for manufacturing and clinical trials.
• The company faces significant competition in the biopharmaceutical industry.

Risks

• The company is a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale.
• The company will require substantial additional financing to achieve its goals, which may not be available on acceptable terms, or at all.
• The company's drug candidates may cause undesirable side effects or have other properties that could delay or halt their clinical development.
• The company faces significant competition, and if competitors develop and market products that are more effective, safer or less expensive, the company's commercial opportunities will be negatively impacted.
• The company may be unable to obtain, maintain, protect and enforce sufficient patent and other intellectual property protection for its drug candidates and technology.

Future Outlook

The company expects its existing cash, cash equivalents and investments will enable it to fund its operations for at least 12 months following the date the condensed consolidated financial statements are issued. The company plans to submit a new Phase 2 protocol under the existing IND in the first quarter of 2025.

Management Comments

• The company is focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections.
• The company has a demonstrated track record of success in drug development and medicinal chemistry in liver and viral diseases.
• The company is exploring ways to boost immune responses via small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-L1) transmembrane protein and its interaction with Programmed Cell Death Protein 1 (PD-1).

Industry Context

The company is operating in a highly competitive biopharmaceutical industry, with numerous companies developing treatments for chronic hepatitis B, MASH, and coronaviruses. The company's focus on differentiated drug candidates and novel mechanisms of action is aimed at addressing unmet medical needs and gaining a competitive advantage.

Comparison to Industry Standards

• The company's Phase 1b data for ALG-000184 indicates a potentially higher proportion of subjects with HBV DNA levels < LLOQ (10 IU/mL) at Week 48 compared to Phase 3 studies with standard of care NAs like tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF).
• ALG-055009 has increased potency (~50-fold greater vs. resmetirom in head-to-head in vitro studies) and selectivity, positioning it as a potential best-in-class THRagonist.
• ALG-097558 has demonstrated broad pan-coronavirus activity, including against SARS-CoV and MERS-CoV, and is at least 6-fold more potent than nirmatrelvir and other PIs in clinical development against a panel of SARS-CoV-2 variants.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• Employees may benefit from the company's equity incentive plans.
• Patients may benefit from the development of new therapies for chronic hepatitis B, MASH, and coronaviruses.
• The company's suppliers and manufacturers may be affected by the company's financial performance and development activities.

Next Steps

• Dosing of HBeAg positive and HBeAg negative subjects with ALG000184 ETV will continue throughout 2024.
• Phase 2b enabling activities for ALG-055009 are underway, with expected completion in the middle of 2025.
• ALG-097558 is expected to begin three additional clinical trials in the fourth quarter of 2024.
• The company plans the submission of a new Phase 2 protocol under the existing IND for ALG-000184 in the first quarter of 2025.

Key Dates

Keywords

Aligos Therapeutics, clinical-stage, biopharmaceutical, hepatitis B, MASH, coronavirus, ALG-000184, ALG-055009, ALG-097558, clinical trials, drug development, financial results